Last reviewed · How we verify

NCT04451694: NutriCoviDom

Nutritional Follow up After Hospital Discharge for Coronavirus Disease-19

Status unknown Last updated 30 June 2020
What this trial tests

trial testing nutritional intervention in Covid-19 in 800 participants. Status unknown.

Timeline
1 April 2020
Primary endpoint
30 July 2020
30 November 2020

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment800
Start date1 April 2020
Primary completion30 July 2020
Estimated completion30 November 2020
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

16 and older, any sex, with Covid-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Coronavirus infection is responsible for muscle wasting (sarcopenia), especially during prolonged stays in intensive care. Sarcopenia, in its functional aspect also seems major in patients hospitalized for this infection, in non-ICU unit. Weight loss also appears to be significant, despite a prevalence of overweight and obesity in severe forms. Undernutrition in the obese patient is also possible (undernourished obese and sarcopenia obesity). Anosmia and dysgeusia participate in undernutrition by reducing energy intake. The rehabilitation of these patients requires nutritional support (increased protein intake) associated with progressive retraining to physical activity. An early and proactive management procedure within Coronavirus disease-19 units has been implemented in conjunction with the Transversal Nutrition Unit (TNU). This nutritional care must be continued after discharge. Follow-up by teleconsultation or telephone consultation is put in place after the patient's discharge Primary Objective: Evaluation of nutritional status at the time of admission and discharge and home follow-up in outgoing patients from Coronavirus disease-19 Units Secondary objectives: Description of the evolution of food intake, diversity of food and coverage of needs Evaluation of the muscular strength of the wrist (by grip test in hospital) and on the arms and legs after return home (visual analog scale) Evolution of anosmia and dysgeusia (at the time of hospital admission, at the time of hospital discharge and at home) Level of physical training before infection (IPAQ) Description of the general state of health measured by the performance index - world health organization scale Description of nutritional prescriptions Description of the prevention measures and incidence of Inappropriate Refeeding Syndrome (IRS) Care needs assessments

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Long-Term Evolution of Malnutrition and Loss of Muscle Strength after COVID-19: A Major and Neglected Component of Long COVID-19.
    Gérard M, Mahmutovic M, Malgras A, Michot N, et al · · 2021 · cited 45× · PMID 34836219 · DOI 10.3390/nu13113964
  2. Impact of severe SARS-CoV-2 infection on nutritional status and subjective functional loss in a prospective cohort of COVID-19 survivors.
    Quilliot D, Gérard M, Bonsack O, Malgras A, et al · · 2021 · cited 19× · PMID 34261689 · DOI 10.1136/bmjopen-2021-048948
  3. Assessment of dynapenia and undernutrition in primary care, a systematic screening study in community medicine.
    Treuil M, Mahmutovic M, Di Patrizio P, Nguyen-Thi PL, et al · · 2023 · cited 4× · PMID 37739706 · DOI 10.1016/j.clnesp.2023.08.003

Verify or expand the search:

Other trials of nutritional intervention

Trials testing the same drug.

Other recruiting trials for Covid-19

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04451694.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing